Intraocular Pressure-Lowering Effect of Netarsudil Across Glaucoma Severity.
文献摘要
Precis Netarsudil lowered IOP across all glaucoma severity stages; however, its durability appeared reduced in patients with systemic hypertension, suggesting the need for closer follow-up. Purpose To evaluate the intraocular pressure (IOP)-lowering effect of netarsudil 0.02% across different stages of glaucoma severity and to investigate the influence of systemic hypertension on treatment response over time. Methods This retrospective study included 113 eyes of 113 patients with glaucoma who initiated netarsudil 0.02% between December 2024 and December 2025. Patients were classified into early (mean deviation [MD] >-6 dB), moderate (-6 to -12 dB), and advanced ( Results Baseline IOP was comparable across severity groups. Netarsudil produced a significant reduction in IOP over time (P Conclusions Netarsudil was associated with a significant IOP-lowering effect across all stages of glaucoma, without significant differences according to disease severity. However, the durability of its effect may be influenced by systemic hypertension, suggesting the need for closer monitoring in hypertensive patients.